Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”
Angela L. Bosma(Amsterdam University Medical Centers), Phyllis I. Spuls, Louise A. A. Gerbens(Amsterdam UMC Location University of Amsterdam), Linde E. M. de Wijs(Erasmus MC), DirkJan Hijnen, Michel H. Hof(Amsterdam University Medical Centers), Maritza A. Middelkamp‐Hup(Amsterdam University Medical Centers), Beau R. van Nieuwenhuizen(Amsterdam University Medical Centers)
Cited by 0
Related Papers
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
|Journal of Clinical Oncology|2015|619
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
|Journal of the European Academy of Dermatology and Venereology|2022|419
Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder
|Journal of Investigative Dermatology|2016|377
Absence of T-regulatory cell expression and function in atopic dermatitis skin
|Journal of Allergy and Clinical Immunology|2005|272